An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Clinical trial NCT05223816 · RECRUITING
Trial details
- NCT number
- NCT05223816
- Sponsor
- Virogin Biotech Canada Ltd
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-24
- Primary completion
- 2025-10-01
- Enrollment
- 97
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.